Bristol-Myers offloads anti-tau, DMD assets to Biogen, Roche for $470M upfront, $615M in milestones | Fierce Biotech
Overview of Tau immunotherapies in clinical trial. Indicated are... | Download Scientific Diagram
Medscape - After disappointing trial results, Biogen will discontinue development of gosuranemab for PSP and other primary tauopathies. http://ms.spr.ly/6185Tn3JH | Facebook
Biogen Licenses Phase 2 Anti-Tau Antibody from Bristol-Myers Squibb - Pharmaceutical Processing World
Biogen - Pioneers In Neuroscience
Cover Layout Presentation name
Biogen Cancels Another Dementia Drug in Phase 2 Clinical Trial - Being Patient
Biogen deals the tau pipeline another blow | Evaluate
Biogen Headquarters And Global Offices
pspawareness - Twitter Search / Twitter
Anti-Tau Drugs for PSP Move into Phase II - CurePSP
Safety and efficacy of anti-tau monoclonal antibody gosuranemab in progressive supranuclear palsy: a phase 2, randomized, placebo-controlled trial | Nature Medicine
Research | Pipeline
Biogen May Cut Jobs, Shutter Facilities to Streamline Ops and Free Up $400 Million for R&D | BioSpace
Biogen on Twitter: "Our #MultipleSclerosis (#MS) and progressive supranuclear palsy (#PSP) research will be highlighted in the poster sessions today at #AANAM https://t.co/4HA0yQOW8X" / Twitter
Research - Tau Consortium
Biogen abandons tau antibody for Alzheimer's after phase 2 miss -
Biogen pays $300M to Bristol-Myers for another potential Alzheimer's drug - Boston Business Journal
Biogen chalks up another failure, but investors' eyes remain firmly on Alzheimer's | Fierce Biotech
Cure PSP - Can Progressive Supranuclear Palsy (PSP) be treated at all? The PASSPORT trial is investigating whether a new investigational study drug may slow the progression of PSP. Biogen plan to
Biogen MA Inc. 225 Binney Street Cambridge, MA 02142 United States PROTOCOL NUMBER: 251PP301 / NCT03068468 Biogen Idec Research
PSP — Coleen Heaver
Biogen looks to M&A to overcome competition to its MS franchise | Fierce Pharma
Gosuranemab: another Alzheimer's candidate to bite the dust
Biogen's Tau Antibody for Progressive Supranuclear Palsy Fails Trial | BioSpace
Biogen 2019 Outlook (NASDAQ:BIIB) | Seeking Alpha
